Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

BACKGROUND: This Phase I study evaluated continuous- and intermittent-dosing (every other week) of afatinib plus nintedanib in patients with advanced solid tumours. METHODS: In the dose-escalation phase (n=45), maximum tolerated doses (MTDs) were determined for continuous/intermittent afatinib 10, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahleda, Rastislav, Hollebecque, Antoine, Varga, Andrea, Gazzah, Anas, Massard, Christophe, Deutsch, Eric, Amellal, Nadia, Farace, Françoise, Ould-Kaci, Mahmoud, Roux, Flavien, Marzin, Kristell, Soria, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815889/
https://www.ncbi.nlm.nih.gov/pubmed/26512876
http://dx.doi.org/10.1038/bjc.2015.374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815889/
https://www.ncbi.nlm.nih.gov/pubmed/26512876
http://dx.doi.org/10.1038/bjc.2015.374

Ejemplares similares